What it's for (Indications)
- This fixed-dose combination, containing rifampicin, isoniazid, ethambutol, and pyrazinamide (RHZE), is specifically indicated for the initial intensive phase treatment of pulmonary and extrapulmonary tuberculosis (TB) caused by susceptible strains of *Mycobacterium tuberculosis*.
- It is a cornerstone therapy in new, previously untreated cases of active tuberculosis and may also be utilized in certain retreatment regimens under strict medical supervision and susceptibility testing.
- The combination therapy aims to rapidly reduce the bacterial load, prevent the emergence of drug resistance, and achieve cure, forming the foundation of short-course antituberculosis treatment strategies recommended by global health organizations.
- Its use ensures adherence to complex multi-drug regimens, which is critical for successful TB eradication and public health.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of this fixed-dose combination (FDC) is determined based on the patient's body weight and the specific phase of tuberculosis treatment, typically administered daily during the intensive phase. It is crucial to follow the prescribed regimen meticulously, as deviations can lead to treatment failure or the development of drug resistance. The FDC simplifies administration by providing all four critical drugs in a single tablet, thereby improving patient adherence. However, individual drug components within the FDC are present in specific fixed ratios, which might necessitate individual component adjustment or careful consideration in patients with significant organ dysfunction, particularly renal or hepatic impairment. Close medical supervision, including monitoring for efficacy and adverse effects, is essential throughout the entire treatment course to optimize outcomes and minimize risks. |
Safety & Warnings
Common Side Effects
- Treatment with this four-drug combination can lead to a range of side effects, some of which are serious and require immediate medical attention.
- Common gastrointestinal disturbances include nausea, vomiting, abdominal pain, and loss of appetite.
- Skin reactions such as rash, pruritus, and rarely severe cutaneous adverse reactions may occur.
- Rifampicin imparts a harmless red-orange discoloration to urine, sweat, tears, and other bodily fluids, which patients should be counselled about.
- Significant and potentially severe adverse effects include hepatotoxicity (inflammation of the liver), presenting as elevated liver enzymes, jaundice, dark urine, and malaise, which is a major concern.
- Peripheral neuropathy, characterized by tingling or numbness in extremities, is primarily associated with isoniazid.
- Optic neuritis, manifesting as blurred vision, visual field defects, or red-green color blindness, is a key concern with ethambutol.
- Pyrazinamide can cause hyperuricemia, potentially leading to gouty arthritis, and arthralgia.
- Other possible effects include flu-like syndrome, thrombocytopenia, hemolytic anemia, and psychiatric disturbances.
- Regular monitoring for adverse reactions and prompt reporting of any new or worsening symptoms are paramount.
Serious Warnings
- Black Box Warning: ### SERIOUS WARNINGS: SEVERE HEPATOTOXICITY, PERIPHERAL NEUROPATHY, AND OPTIC NEURITIS This fixed-dose combination carries a significant risk of severe and potentially fatal adverse reactions, necessitating careful patient selection, thorough baseline assessment, and diligent ongoing monitoring. **Severe and sometimes fatal hepatotoxicity** has been reported with rifampicin, isoniazid, and pyrazinamide, individually and in combination. Patients must undergo baseline and regular monitoring of liver function tests (LFTs) throughout the treatment course, especially in the initial weeks. Education on symptoms of liver injury (e.g., unexplained fatigue, weakness, malaise, anorexia, nausea, vomiting, dark urine, yellow discoloration of the eyes or skin, right upper quadrant tenderness) is crucial, and the medication should be promptly discontinued if significant liver dysfunction occurs. **Peripheral neuropathy**, a serious dose-related adverse effect predominantly associated with isoniazid, can lead to permanent neurological damage if not promptly recognized and managed with concomitant pyridoxine (Vitamin B6) supplementation, which is strongly recommended for all patients, particularly those at higher risk. **Optic neuritis**, a severe ocular toxicity linked to ethambutol, is dose- and duration-dependent and can result in irreversible vision loss, including diminished visual acuity and red-green color blindness. Baseline and periodic ophthalmologic examinations, including visual acuity and color discrimination testing, are mandatory. Patients must be instructed to report any visual changes (e.g., blurred vision, central scotoma, loss of red-green discrimination) immediately. These substantial risks necessitate a thorough individualized risk-benefit assessment before initiation, close clinical observation for signs and symptoms of adverse reactions, and systematic laboratory and ophthalmologic surveillance throughout the entire treatment period.
- Several critical warnings are associated with the use of this four-drug combination.
- **Hepatotoxicity** is a significant risk, and patients must be closely monitored for signs and symptoms of liver injury, including routine liver function tests (LFTs).
- Concomitant alcohol consumption, pre-existing liver disease, or age over 35 years increases this risk substantially.
- **Ocular toxicity**, specifically optic neuritis leading to vision impairment, is a dose-related concern with ethambutol; baseline and regular ophthalmological examinations, including color vision testing, are crucial, especially in patients on prolonged therapy or with renal impairment.
- **Peripheral neuropathy**, predominantly caused by isoniazid, can be prevented or mitigated with concomitant pyridoxine (vitamin B6) supplementation, especially in malnourished patients, diabetics, alcoholics, or those with renal failure.
- Significant **drug interactions** are common due to rifampicin's potent induction of cytochrome P450 enzymes, affecting the metabolism of many drugs including oral contraceptives (requiring alternative contraception), antiretrovirals, anticoagulants (requiring INR monitoring), and corticosteroids.
- **Hyperuricemia** and acute gout attacks can be precipitated by pyrazinamide and, to a lesser extent, ethambutol.
- Patients should be advised to report any visual changes, numbness, tingling, joint pain, or signs of liver dysfunction (e.
- g.
- , jaundice, dark urine, persistent fatigue) immediately.
- Renal impairment requires careful dose adjustment of ethambutol and pyrazinamide.
How it Works (Mechanism of Action)
This fixed-dose combination exerts its potent antitubercular activity through the synergistic actions of its four distinct components, each targeting unique mycobacterial pathways to ensure comprehensive bactericidal and bacteriostatic effects. **Rifampicin** acts by inhibiting bacterial DNA-dependent RNA polymerase, thereby blocking RNA synthesis in susceptible *Mycobacterium tuberculosis* and other bacteria. **Isoniazid (INH)**, a prodrug, is activated by mycobacterial catalase-peroxidase (KatG) to form reactive intermediates that inhibit the synthesis of mycolic acids, essential components of the mycobacterial cell wall, leading to cell lysis. **Ethambutol** interferes with arabinosyl transferases (EmbA, EmbB, EmbC), enzymes crucial for the biosynthesis of the arabinogalactan layer in the mycobacterial cell wall, leading to increased cell wall permeability and disruption of cell integrity. **Pyrazinamide (PZA)**, also a prodrug, is converted to pyrazinoic acid (POA) by mycobacterial pyrazinamidase (PncA) in acidic intracellular environments, particularly within macrophages. POA disrupts mycobacterial cell membrane function, fatty acid synthesis, and potentially energy metabolism, making it uniquely effective against non-replicating persistent bacilli. The combined action targets multiple mycobacterial pathways, ensuring broad-spectrum activity, preventing the emergence of drug resistance, and facilitating rapid bacterial clearance.
Commercial Brands (Alternatives)
No other brands found for this formula.